Compare · AVTX vs NVO
AVTX vs NVO
Side-by-side comparison of Avalo Therapeutics Inc. (AVTX) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVTX and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 203.5x AVTX ($1.06B).
- AVTX has been more active in the news (12 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 20 for AVTX).
- Company
- Avalo Therapeutics Inc.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- $1.06B
- $215.46B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2015
- News (4w)
- 12
- 9
- Recent ratings
- 20
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest AVTX
- Chief Financial Officer Sullivan Christopher Ryan sold $1,450,419 worth of shares (72,725 units at $19.94) as part of a pre-agreed trading plan and exercised 71,852 shares at a strike of $9.88, decreasing direct ownership by 2% to 39,900 units (SEC Form 4)
- Chief Medical Officer Doyle Mittie exercised 1,000 shares at a strike of $12.65 and sold $20,000 worth of shares (1,000 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- Chief Strategy Officer Riley Jennifer sold $52,012 worth of shares (2,655 units at $19.59), decreasing direct ownership by 7% to 37,041 units (SEC Form 4)
- Chief Medical Officer Doyle Mittie exercised 679 shares at a strike of $8.04 and sold $13,580 worth of shares (679 units at $20.00) as part of a pre-agreed trading plan (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- SEC Form SCHEDULE 13G filed by Avalo Therapeutics Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Avalo Therapeutics Inc.
- SEC Form 10-Q filed by Avalo Therapeutics Inc.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S